Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT502 in Rheumatoid Arthritis
NCT07564154Phase 1Recruiting
- Sponsor
- KaliVir Immunotherapeutics
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of KT502 in rheumatoid arthritis (RA) (2 arms), sponsored by KaliVir Immunotherapeutics. Primary endpoints: Incidence of Adverse Events at 12 weeks, Incidence of Cytokine-release Syndrome at 12 weeks and 9 more. Started Jul 2026; status: recruiting.
02
Drugs
KT502
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07564154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564154.